Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells
Open Access
- 22 September 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 12 (12), 1205-1219
- https://doi.org/10.1093/neuonc/noq103
Abstract
Glioblastoma, the most intractable cerebral tumor, is highly lethal. Recent studies suggest that cancer stem-like cells (CSLCs) have the capacity to repopulate tumors and mediate radio- and chemoresistance, implying that future therapies may need to turn from the elimination of rapidly dividing, but differentiated, tumor cells to specifically targeting the minority of tumor cells that repopulate the tumor. However, the mechanism by which glioblastoma CSLCs maintain their immature stem-like state or, alternatively, become committed to differentiation is poorly understood. Here, we show that the inactivation of mammalian target of rapamycin (mTor) by the mTor inhibitor rapamycin or knockdown of mTor reduced sphere formation and the expression of neural stem cell (NSC)/progenitor markers in CSLCs of the A172 glioblastoma cell line. Interestingly, combination treatment with rapamycin and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, not only reduced the expression of NSC/progenitor markers more efficiently than single-agent treatment, but also increased the expression of βIII-tubulin, a neuronal differentiation marker. Consistent with these results, a dual PI3K/mTor inhibitor, NVP-BEZ235, elicited a prodifferentiation effect on A172 CSLCs. Moreover, A172 CSLCs, which were induced to undergo differentiation by pretreatment with NVP-BEZ235, exhibited a significant decrease in their tumorigenicity when transplanted either subcutaneously or intracranially. Importantly, similar results were obtained when patient-derived glioblastoma CSLCs were used. These findings suggest that the PI3K/mTor signaling pathway is critical for the maintenance of glioblastoma CSLC properties, and targeting both mTor and PI3K of CSLCs may be an effective therapeutic strategy in glioblastoma.This publication has 56 references indexed in Scilit:
- Dynamic FoxO transcription factorsJournal of Cell Science, 2007
- A rapid assay for drug sensitivity of glioblastoma stem cellsBiochemical and Biophysical Research Communications, 2007
- Genetic Pathways to Primary and Secondary GlioblastomaThe American Journal of Pathology, 2007
- Cancer Stem Cells: Models and ConceptsAnnual Review of Medicine, 2007
- Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosisRadiotherapy and Oncology, 2007
- FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell HomeostasisCell, 2007
- FOXO3a Induces Differentiation of Bcr-Abl-transformed Cells through Transcriptional Down-regulation of Id1Online Journal of Public Health Informatics, 2007
- Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cellsNature, 2006
- Brain tumour stem cellsNature Reviews Cancer, 2006
- Therapeutic implications of cancer stem cellsCurrent Opinion in Genetics & Development, 2004